Anpario PLC (ANP) — Investment Research Note

Executive summary

Anpario is a UK-based AIM-listed independent manufacturer of natural, sustainable animal feed additives (phytogenics, acid-based eubiotics, mycotoxin binders, pellet binders, omega-3) sold into >70 countries for poultry, swine, ruminant and aquaculture producers. The trajectory across the five-year window is U-shaped: revenue dipped from £33.4m (2021) to £31.0m (2023) under agriculture-sector destocking and raw material inflation, then accelerated to £38.2m (2024) and £47.2m (2025, +24%) helped by the September 2024 Bio-Vet US acquisition (£6.7m FY revenue contribution) plus 12% like-for-like growth, with gross margin recovering to 50.9% and adjusted EBITDA reaching £9.6m. The single most important valuation point today is that the business has just printed peak profits with full Bio-Vet contribution and demonstrable operating gearing, but the shares are not obviously cheap — investors are paying ~13x trailing EPS for a niche, well-managed specialty additives business with no meaningful AI exposure.

Fair value estimate

• Fair value range: 480 – 600p per share (implied market cap £99m – £124m)
• Methodology: Blended forward P/E (13–16x on 2026e diluted adjusted EPS of ~37–38p, modest deceleration vs 2025's exceptional 39.49p given Middle East disruption commentary and tough Q1 comparator) cross-checked against EV/EBITDA (9–11x on £9.6m 2025 EBITDA less £12.4m net cash). Both methods triangulate to a similar range. Anpario deserves a small premium to small-cap UK specialty chemicals due to net-cash balance sheet, recurring product franchise (Orego-Stim®, pHorce®, Mastercube®) and exposure to long-term natural-additive regulatory tailwinds, but a discount to large-cap animal nutrition due to AIM liquidity and customer cyclicality.
• Current mcap £106.9m sits within the range. Mid-point fair value ~£112m implies ~5% upside; range spans -8% to +16%.
• View: fair, with mild positive skew.

Sector context

• Classification confirmed: Consumer Staples / Food, Beverage & Tobacco — accurate, though Anpario is effectively a specialty chemicals / animal-nutrition niche within that bucket.
• Quality profile: gross margin (50.9%) and net-cash balance sheet are above typical food/beverage staples peers; growth (24% reported, 12% LFL) is well above the staples sector average. Leverage is well below sector peers.
• Listed comparables: Carr's Group (CARR.L) in UK agri-supplies (very different business model); Benchmark Holdings (BMK.L) in aquaculture genetics/health; further afield, Phibro Animal Health (PAHC.US), Adisseo (private/SHV), Alltech (private), Kemin (private). The cleanest listed comps are likely Phibro and Benchmark.

Investment thesis (3 bullets)

1. Demonstrated operating leverage with margin upside intact — Revenue +24% drove adjusted EBITDA +38% and gross margin from 46.9% to 50.9%; CEO explicitly cites "operational leverage inherent in our business model" 2026-03 final results. With Bio-Vet integration ongoing and combined Americas cross-selling not yet annualised, further LFL margin expansion is plausible.
2. Bio-Vet acquisition is working — Acquired Sep-2024 for $7.4m, earn-out fully achieved, H2 2025 was one of Bio-Vet's strongest-ever six-month performances; gives the group a US production site, ruminant expertise and a direct-fed microbial portfolio (Generator™, QuadriCal®, RumenAider®) to globalise via Anpario's existing network 2026-03 final results; 2024-09 acquisition.
3. Fortress balance sheet with capital return discipline — Net cash £12.4m at YE 2025 after paying £2.1m dividends and final $1m Bio-Vet contingent consideration; £9m tender offer completed July 2023 cancelled 4.4m shares; dividend +11% in 2025; supports either further bolt-ons or shareholder returns without dilution 2026-03 final results; 2023-09 interims.

Key risks (3 bullets)

1. Geopolitical / shipping disruption — Iran/Middle East conflict explicitly flagged as affecting Persian Gulf logistics in 2026 outlook; UAE was largest Middle East contributor in 2025 2026-03 final results. Avian influenza and African Swine Fever are recurrent regional shocks.
2. Brazil structural weakness and customer concentration risk in tendered products — Brazil sales -22% in 2025, -33% in H1; competition from local producers not subject to import tariffs; Saudi pellet binder business lost; one Egypt customer had credit issues 2026-03 final results; 2025-09 interim. Lower value-add product classes remain price-competitive.
3. AIM small-cap liquidity / concentrated register — Top 9 holders own ~65% of shares (largest is the JTC plc employees' share trust at 18.4%); poor liquidity in AIM small caps is acknowledged by management in the risk register 2026-03 final results.

Operating leverage

The fixed-cost base is the UK Manton Wood manufacturing site (substantially automated over the 2016–2023 capex programme, with on-site bulk storage, automated palletising and dust recirculation) plus a global subsidiary network. Production cost is "largely fixed and semi-fixed" on the CEO's own commentary 2023-09 interim; the H1 2023 trading update noted lower volumes caused under-recovery of overheads — direct evidence of operating leverage in reverse. In 2025, revenue +24% (or +12% LFL) drove gross profit +34% and adjusted EBITDA +38%; admin expenses LFL grew only 11% versus 12% LFL revenue. Gross margin moved from a 2022/23 trough of 42.7%/45.0% back to 50.9% as volumes recovered. The recently acquired US Barneveld production site doubles fixed capacity. A plausible model: at current scale, incremental LFL revenue probably converts at ~55–60% gross margin and ~35–40% EBITDA margin (vs reported 20% EBITDA margin). A 10–20% revenue surprise above plan could add 30–60% to operating profit — meaningful, but not the "multiples of profit" sensitivity seen in pure software or capacity-constrained services.

Value-trap signals

None of the classic signals are present. Cash generation is strong, dividend is rising, no debt, no related-party transactions, no going-concern issues, auditor unqualified, no regulatory threats, customer concentration absent (no customer >10% of revenue). The 2022–2023 decline was clearly cyclical (industry destocking, raw material inflation, customer margin compression) and has reversed convincingly through 2024–2025. Auditor changed from BDO to HaysMac in 2025 following audit tender — worth noting but not flagged as concerning.

Earnings vs expectations

The filings include three full-year trading updates that explicitly reference analyst consensus: (i) FY2023 update Jan-2024 reported EBITDA "ahead of current market expectations" of not less than £4.4m; (ii) FY2024 update Jan-2025 reported revenue ~£37.5m vs consensus £35.25m and EBITDA ahead vs consensus £5.7m, net cash £10.5m vs £7.2m; (iii) FY2025 update Jan-2026 reported revenue ~£47.1m vs consensus £45.5m, EBITDA not less than £9.4m vs consensus £8.2m, net cash £12.4m vs £12.0m. Pattern: three consecutive meaningful beats on revenue, EBITDA and cash — supported by Jun-2025 AGM trading statement that flagged H1 in line with expectations and ultimate H1 2025 print of £4.1m EBITDA vs £2.7m prior year. The trend is consistently positive surprise since the trough of 2023.

Conviction

Conviction: 4 / 5 (high). Anchored by (i) clean, well-disclosed audited accounts with consistent IFRS treatment, (ii) two valuation methods (P/E and EV/EBITDA) triangulating to similar fair value, and (iii) a five-year audited revenue and margin series that allows a credible normalised earnings view. Limited by (1) 2025 had an exceptional Bio-Vet integration tailwind plus easy comparators that may not repeat at the same magnitude in 2026, and (2) the 2026 outlook explicitly flags Middle East disruption and "high comparator through Q1 last year" — meaning short-term earnings path has wider error bars than the long-term trend.